Mebenda Plus

The two medicines target parasites through different mechanisms.

Mebendazole interferes with tubulin formation in susceptible helminths. This disrupts their cellular structure and glucose utilization, eventually immobilizing and killing the worms. DailyMed

Ivermectin binds selectively to glutamate-gated chloride channels in susceptible parasites. This increases chloride permeability, causing paralysis and death of susceptible organisms. It is active against several nematode life-cycle stages, although its activity varies by parasite. DailyMed

Using two antiparasitic agents together may provide broader activity in selected infections, but the combination should not be assumed to be appropriate for every type of parasite.

The 500 mg + 25 mg tablet strength should not be treated as a universal dose. There is no sufficiently reliable product-specific dosing label available for Mebenda Plus that would justify publishing a single regimen for all patients.

Consideration	Why it matters
Parasite identified	Treatment varies by organism
Age and body weight	Particularly important for ivermectin
Medical history	Liver disease and other conditions can affect treatment decisions
Other medicines	Potential interactions must be reviewed
Combination strength	The fixed 500 mg + 25 mg amounts cannot be independently adjusted without professional advice

For comparison, U.S. mebendazole labeling uses different regimens for pinworm, whipworm, roundworm and hookworm, while ivermectin labeling uses weight-based dosing for strongyloidiasis and onchocerciasis. DailyMed

Do not calculate an individual dose, repeat treatment, or substitute another ivermectin or mebendazole strength without advice from a doctor or pharmacist.

Mebenda Plus is marketed as a combination antiparasitic medicine for worm infections. However, an authoritative product-specific prescribing label for this exact 500 mg + 25 mg fixed-dose combination was not located, so individual indications should not be presented as if they were formally approved for this brand.

• Mebendazole is established for gastrointestinal infections caused by pinworm, roundworm, hookworm and whipworm. DailyMed
• Ivermectin is approved in U.S. labeling for intestinal strongyloidiasis and onchocerciasis. DailyMed
• Combination research: A randomized controlled trial in children with Trichuris trichiura found that adding ivermectin to mebendazole improved cure and egg-reduction outcomes compared with mebendazole alone. This evidence does not establish that every patient with a worm infection should receive this fixed-dose product. PubMed
• Other uses should be based on the diagnosed parasite, patient characteristics and local treatment guidance.

Possible effects from mebendazole include abdominal pain, diarrhea, flatulence, nausea, vomiting and rash. Higher doses or prolonged treatment have been associated with more serious blood and liver-related adverse effects. DailyMed

Ivermectin can cause dizziness, drowsiness and gastrointestinal symptoms, while more serious neurological reactions have also been reported. DailyMed

Important interaction precautions include:

• Metronidazole: U.S. mebendazole labeling advises avoiding concomitant use because serious skin reactions, including Stevens-Johnson syndrome/toxic epidermal necrolysis, have been reported. DailyMed
• Warfarin: Ivermectin has rarely been associated with increased INR when co-administered with warfarin. DailyMed
• Tell the prescriber about all prescription medicines, OTC products and supplements before treatment.

Because the exact Mebenda Plus prescribing leaflet was not located, the product pack and prescriber instructions should take priority over generic instructions for either ingredient alone.

• Take the medicine only in the dose and schedule prescribed.
• Do not assume that the dosing instructions for standalone mebendazole or ivermectin apply to this fixed-dose combination.
• Do not combine it with additional ivermectin or mebendazole unless specifically instructed.
• Check the blister and carton for the correct 500 mg + 25 mg strength before use.
• Keep the medicine in its original packaging and away from children.
• Use the storage conditions printed on the actual Mebenda Plus pack; an exact product-specific storage temperature could not be independently verified.

The available packaging shows 10 × 10 tablets and the Rx designation.

Do not use Mebenda Plus if you have a known hypersensitivity to mebendazole, ivermectin or an ingredient in the formulation. Because the exact fixed-dose product label was not located, the safety profile of the combination should not be inferred solely from either ingredient's individual label.

Mebendazole requires particular caution with metronidazole, which should be avoided because of reported serious skin reactions. Higher-dose or prolonged mebendazole treatment can also be associated with neutropenia and agranulocytosis. DailyMed Ivermectin requires additional caution in people with significant exposure to Loa loa-endemic areas because serious neurological reactions can occur in heavily infected individuals. DailyMed

Pregnant or breastfeeding patients should discuss treatment with a healthcare professional before use. Pediatric treatment should not be extrapolated from the 500 mg + 25 mg adult-strength tablet without appropriate professional guidance. Mebendazole labeling also reports limited pregnancy and lactation data, while ivermectin labeling contains specific pregnancy and pediatric precautions. DailyMed

Seek urgent medical attention for severe allergic reactions, seizures, major confusion, loss of coordination, severe skin reactions or other serious symptoms.

This information is for general education and does not replace advice from a doctor, pharmacist or qualified healthcare professional.